In SW403 and LNCaP cells, carmofur reduced AC activity and increased selected ceramide species. Separate 5-FU treatment did not reproduce the short-term lipid response. These experiments establish cellular pharmacodynamic effects in the tested models. [1]
In fibroblasts from one Krabbe patient, 3 µM carmofur for two weeks decreased psychosine and increased ceramides relative to vehicle. Replicate cultures from one donor do not establish a response across patients. [3]
Rat acid ceramidase inhibition and kinetic characterization
Biochemical assay · Recombinant rat acid ceramidase [1]
Carmofur inhibited AC; 5-FU was much weaker. Reduced maximal velocity, time-dependent onset and partial recovery after dialysis qualify the inhibition mechanism.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response; kinetic comparisons at 20 and 60 nM; dialysis experiment at 200 nM.
- Exposure duration
- Activity reaction: 30 min; preincubation varied in Fig. 1C; dialysis: 12 h.
- Method
- LC/MS quantification of lauric acid released from N-lauroyl ceramide; pH 4.5, 37 °C.
- Vehicle
- DMSO 1% in kinetic comparison (Fig. 1B).
- Co-treatment
- None; comparator treatments are separate controls.
- Reported limits
- A single preincubation time for the potency fit is not specified in the read assay description; do not transfer the time-course peak to that fit.
Methods and source locations
Compound reported in the paper: Carmofur; Compound label in the paper: Carmofur
Research findings for the reported material and model; no supplier-lot equivalence or clinical efficacy inference.
Results: Carmofur is a highly potent AC inhibitor; Fig. 1A–D; Tables 1–2; SI Acid Ceramidase Activity
AC inhibition: LC/MS enzyme assay; value printed in text/table, not estimated from curve. — Results first paragraph; Table 1; Fig. 1A caption
5-FU inhibition of rat AC: Separate comparator in the same enzyme assay. — Results first paragraph; Fig. 1A
Onset and recovery of AC inhibition: Preincubation time course and overnight dialysis with vehicle controls. — Results first paragraph; Fig. 1C–D
Cellular AC inhibition and ceramide accumulation
Cell-based study · Human SW403 colon adenocarcinoma and LNCaP prostate adenocarcinoma cells [1]
Carmofur lowered cellular AC activity and increased ceramide species in these models. Separate 5-FU treatment did not reproduce the short-term AC/ceramide response.
Literature-Reported Treatment Conditions
- Treatment concentration
- SW403: 0.3–10 µM; LNCaP graphic: 0.3–3 µM for AC concentration response; 3 µM in time-course/lipid experiments; separate 5-FU 3 µM.
- Exposure duration
- 3 h for concentration response; 20 min–6 h AC time course; 1, 3 and 6 h shown for ceramides.
- Method
- Drug treatment of intact cells; AC activity in lysates by LC/MS and cellular ceramides by LC/MS.
- Vehicle
- 0.1% DMSO; vehicle and separate 5-FU controls.
- Co-treatment
- None; comparator treatments are separate controls.
- Reported limits
- Main Fig. 2 caption gives a general 0.3–10 µM range, while LNCaP panel D displays through 3 µM. Caption describes 3-h lipid treatment but panels also show 1 and 6 h; retain panel-specific scope.
Methods and source locations
Compound reported in the paper: Carmofur; Compound label in the paper: Carmofur
Research findings for the reported material and model; no supplier-lot equivalence or clinical efficacy inference.
Fig. 2A–F and caption; Results first section; SI Tables S1–S2 and AC/lipid methods
Cellular AC activity: Activity measured in lysates after intact-cell treatment; vehicle and 5-FU controls. — Fig. 2A–B, D–E and caption
Cellular ceramide species: LC/MS; no exact bar-derived concentrations adopted. — Fig. 2C,F; SI Tables S1–S2
Human AC structure with a carmofur-derived covalent adduct
Biochemical assay · Recombinant mature human acid ceramidase; X-ray crystal structure, PDB 6MHM [2]
The observed carmofur-derived moiety is covalently linked to catalytic Cys143 and occupies a hydrophobic region of the substrate-binding pocket.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 mM carmofur in complex-formation mixture (structural preparation, not an IC50).
- Method
- X-ray crystallography and molecular replacement with activated apo-AC (5U7Z) as search model; electron-density interpretation.
- Vehicle
- DMSO stock and aqueous Triton X-100 used for complex formation; final DMSO fraction not specified in read text.
- Co-treatment
- None; comparator treatments are separate controls.
- Reported limits
- Complex-formation incubation time not specified in read text. This is structural evidence, not a new potency or cellular efficacy determination.
Methods and source locations
Compound reported in the paper: Carmofur; Compound label in the paper: Carmofur
Research findings for the reported material and model; no supplier-lot equivalence or clinical efficacy inference.
Results: Overall structure and Inhibitor binding; Table 1; Fig. 2A–B; Experimental Section: complex formation and structure determination
Covalent modification of human AC: Original Fig. 2 viewed; density shown at 1σ. — Inhibitor binding; Fig. 2A–B and caption
Diffraction resolution: X-ray crystallography; Table 1 read directly from retained HTML. — Table 1: data collection resolution range
Lipid response in Krabbe patient fibroblasts
Cell-based study · Primary human fibroblasts GM04517 from one 8-month-old Krabbe patient; homozygous GALC exons 11–17 deletion [3]
Carmofur decreased psychosine and increased ceramides compared with vehicle in this single-donor cell model.
Literature-Reported Treatment Conditions
- Treatment concentration
- 3 µM
- Exposure duration
- 2 weeks; fresh drug/vehicle with daily complete medium replacement.
- Method
- Cell treatment followed by mass-spectrometric psychosine and ceramide measurement.
- Vehicle
- DMSO control; final percentage not specified in read paragraph.
- Co-treatment
- None; comparator treatments are separate controls.
- Reported limits
- One donor; six biological replicates per condition are cultures, not six patients.
Methods and source locations
Compound reported in the paper: Carmofur; Compound label in the paper: Carmofur
Research findings for the reported material and model; no supplier-lot equivalence or clinical efficacy inference.
Fig. 5B–C and caption; Mouse and Human Fibroblast Manipulations (human treatment paragraph); Mass Spectrometry; Statistical Analysis
Psychosine and ceramide abundance: Mass spectrometry; mean ± 1 SEM in general statistics; symbol thresholds from Fig. 5 caption; original graphic viewed. — Fig. 5B–C; human fibroblast methods; Statistical Analysis